← Leaderboards
Richard Nowak
Yale University
$1,131,070
Attributed
$4,524,279
Total exposure
1
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.3M · FY2013–16$2M$1.5M$1M$500K$0
'13
'14
'15
'16
Funding mix
By agency
NIH$4,524,279 · 1
By mechanism
U01$4,524,279 · 1
Top collaborators
- Richard J. Barohn5 shared
- Jonathan M. Goldstein5 shared
- David A. Hafler5 shared
Most similar at Yale University
Same institution · by research overlap
- Kevin C O'Connor$6,561,949
- Meenakshi Alreja$2,438,822
- Vasilis Vasiliou$20,612,734
- George Tellides$10,774,220
- Jordan S Pober$30,894,969
Others in their field
Top investigators on “Acetylcholinesterase Inhibitors”
- Janice E. Chambers · Mississippi State University$8,468,221
- Jose Ricardo Suarez · University Of Minnesota$5,982,059
- Anthony O Caggiano · Cognition Therapeutics, Inc.$5,774,586
- Susan M Catalano · Cognition Therapeutics, Inc.$5,735,586
- Patricio Sepulveda · Amplo Biotechnology, Inc.$5,506,739
- Paul A. Newhouse · University Of Vermont &St Agric College$5,375,126
Research focus
Acetylcholinesterase InhibitorsAdrenal Cortex HormonesActivities Of Daily LivingAdverse EventAdvisory CommitteesAffectAmericasAdverse EffectsAreaAutoimmune DiseasesAutoimmunityAzathioprineBaseBiological MarkersBlood SpecimenB-LymphocytesClinical TrialsAntigensCyclosporineDesignDoseDouble-Blind MethodEffectivenessEfficacy Trial
Grant awards (5)
A Phase II Trial of Rituximab In Myasthenia Gravis$964,955
U01 · FY2016 · NS · contact PI
A Phase II Trial of Rituximab In Myasthenia Gravis$183,022
U01 · FY2016 · NS · contact PI
A Phase II Trial of Rituximab In Myasthenia Gravis$1,011,907
U01 · FY2015 · NS · contact PI
A Phase II Trial of Rituximab In Myasthenia Gravis$1,059,022
U01 · FY2014 · NS · contact PI
A Phase II Trial of Rituximab In Myasthenia Gravis$1,305,373
U01 · FY2013 · NS · contact PI